Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial by Pujade-Lauraine, E, Selle, F, Scambia, G, Asselain, B, Marmé, F, Lindemann, Kristina Yvonne Kathe, Colombo, N, Mądry, R, Glasspool, R, Vergote, I, Korach, J, Lheureux, S, Dubot, C, Oaknin, A, Zamagni, C, Heitz, F, Gladieff, L, Rubio-Pérez, M.J, Scollo, P, Blakeley, C, Shaw, B, Ray-Coquard, I, Redondo, A

Request full text

Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival by Dubot, C., Bernard, V., Sablin, M.P., Vacher, S., Chemlali, W., Schnitzler, A., Pierron, G., Ait Rais, K., Bessoltane, N., Jeannot, E., Klijanienko, J., Mariani, O., Jouffroy, T., Calugaru, V., Hoffmann, C., Lesnik, M., Badois, N., Berger, F., Le Tourneau, C., Kamal, M., Bieche, I.

Get full text

Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database by Kaczmarek, E., Saint-Martin, C., Pierga, J.-Y., Brain, E., Rouzier, R., Savignoni, A., Mouret-Fourme, E., Dieras, V., Piot, I., Dubot, C., Carton, M., Lerebours, F.

Get full text

Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution by Bacrie, J, Laurans, M, Iorio, P, Fourme, E, Pierga, J.Y, Béthune Volters, A, Benzidane, B, Bozec, L, Lerebours, F, Dubot, C, Bensaoula, O, Lefeuvre, D

Get full text

2742 Impact of bowel resection on overall survival after neoadjuvant chemotherapy in advanced epithelial ovarian cancer by Philip, C.A, Pelissier, A, Bonneau, C, Dubot, C, Rouge, T. De la Motte, Nicolas, P, Roman, R

Get full text

Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study by Zenatri, M., Perennec, T., Michon, C., Gernier, F., Grellard, J.-M., Piloquet, F.-X., Dubot-Poitelon, C., Kalbacher, E., Tredan, O., Augereau, P., Pautier, P., Fey, L., Joly, F., Frenel, J.-S.

Get full text

POD-Galerkin reduced order model coupled with neural networks to solve flow in porous media by Allery, C., Béghein, C., Dubot, C., Dubot, F.

Get full text

2878 Identification of actionable genes in head and neck squamous cell carcinoma (HNSCC) using gene expression analyses by Sablin, M.P, Dubot, C, Kamal, M, Rodriguez, J, Jouffroy, T, Girod, A, Calugaru, V, Klijanienko, J, Caly, M, Sastre-Garau, X, Lappartient, E, Mariani, O, Berger, F, Vacher, S, Biáche, I, Tourneau, C. Le

Get full text

2772 Circulating tumor cells kinetics in ovarian carcinoma: correlation with baseline characteristics and CA-125 levels in the randomized ANTHALYA trial evaluating bevacizumab in t... by Cottu, P, Rouge, T. De La Motte, Pautier, P, Provansal, M, Floquet, A, Selle, F, Mouret-Reynier, M.A, Fabbro, M, Kalbacher, E, Piprot, C, Follana, P, Lesoin, A, Medioni, J, Menguy, V, Ghazi, Y, Bidard, F.C, Dubot, C, Joly, F

Get full text

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial by Pignata, Sandro, Lorusso, Domenica, Joly, Florence, Gallo, Ciro, Colombo, Nicoletta, Sessa, Cristiana, Bamias, Aristotelis, Salutari, Vanda, Selle, Frédèric, Frezzini, Simona, De Giorgi, Ugo, Pautier, Patricia, Bologna, Alessandra, Orditura, Michele, Dubot, Coraline, Gadducci, Angiolo, Mammoliti, Serafina, Ray-Coquard, Isabelle, Zafarana, Elena, Breda, Enrico, Favier, Laure, Ardizzoia, Antonio, Cinieri, Saverio, Largillier, Rémy, Sambataro, Daniela, Guardiola, Emmanuel, Lauria, Rossella, Pisano, Carmela, Raspagliesi, Francesco, Scambia, Giovanni, Daniele, Gennaro, Perrone, Francesco, Pignata, S, Lorusso, D, Joly, F, Gallo, C, Colombo, N, Sessa, C, Bamias, A, Salutari, V, Selle, F, Frezzini, S, De Giorgi, U, Pautier, P, Bologna, A, Orditura, M, Dubot, C, Gadducci, A, Mammoliti, S, Ray-Coquard, I, Zafarana, E, Breda, E, Favier, L, Ardizzoia, A, Cinieri, S, Largillier, R, Sambataro, D, Guardiola, E, Lauria, R, Pisano, C, Raspagliesi, F, Scambia, G, Daniele, G, Perrone, F

Get full text

8003 ORAL Experience With Bevacizumab in the Management of Relapsed Ovarian Cancer – a Retrospective Observational Study in Five French Hospitals by Dubot, C, Emile, G.A, Lhomme, C, Asmane, I, Pautier, P, Alexandre, J, Goldwasser, F, Lauraine, E. Pujade, Coquard, I. Ray, Seile, F

Get full text

Valeur pronostique de la cinétique précoce de l’ADN tumoral circulant en cours de chimiothérapie néoadjuvante pour les patientes présentant un cancer épithélial de l’ovaire à un st... by Azais, H., Brochard, C., Benoit, L., Bats, A., Taly, V., Ferron, G., Ray-Coquard, I., Hamizi, S., Abadie-Lacourtoisie, S., Lebreton, C., Venat-bouvet, L., Louvet, C., Favier, L., Lortholary, A., Dohollou, N., Malaurie, E., Dubot, C., Kurtz, J., Blons, H., Laurent-Puig, P.

Get full text

ASTER 70s UNICANCER phase III Trial: Can a genomic prognosticator help tailoring adjuvant systemic treatment for luminal breast carcinoma in elderly women? by Dubot, C, Bourbouloux, E, Mir, O, Kirscher, S, Rigal, O, Ferrero, J.-M, Curé, H, Blot, E, Allouache, D, Cottu, P, Romieu, G, Lefeuvre, C, Malaurie, E, Tubiana-Mathieu, N, Lacroix-Triki, M, Rollot, F, Peyro-Saint-Paul, H, Orsini, C, Bonnetain, F, Brain, E

Get full text

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in... by Berger, Frédérique, Marce, Margaux, Hardy-Bessard, Anne-Claire, Bachelot, Thomas, Bièche, Ivan, Pradines, Anne, De La Motte Rouge, Thibault, Canon, Jean-Luc, André, Fabrice, Clatot, Florian, Lemonnier, Jérôme, Marques, Sandrine, Bidard, François-Clement, Achille, M, Alleaume, C, Ammarguellat, H, Arsene, O, Bachelot, T, Barthelemy, P, Barthier, S, Bernard-Marty, C, Bonichon-Lamichhane, N, Bonnin, N, Bouaita, R, Boudrant, A, Brunel, V-A, Chakiba, C, Cheneau, C, Clatot, F, Dalenc, F, De Gramont, A, de La Motte Rouge, T, Deiana, L, Del Piano, F, Delbaldo, C, Delecroix, V, Derbel, O, Desclos, H, D'Hondt, V, Dohollou, N, Dubot, C, Escande, A, Ferrero, J-M, Foa, C, Frenel, J-S, Gardner, M, Garnier Tixidre, C, Genet, D, Gisserot, O, Gozy, M, Greilsamer, C, Grenier, J, Guinet, F, Hardy-Bessard, A-C, Jacquin, J-P, Joly, L, Lachaier, E, Ladoire, S, Laurenty, A-P, Le Scodan, R, Leduc, N, Levache, C, Lorchel, F, Lortholary, A, Lucas, B, Marques, N, Marti, A, Melis, A, Mille, D, Mollon, D, Moreau, L, Moullet, I, Mouret-Reynier, M-A, Najem, A, Nguyen, S, Orfeuvre, H, Paitel, J-F, Petit, T, Pistilli, B, Plaza, J, Riedl, C, Sabatier, R, Soulie, P, Spaeth, D, Stefani, L, Teixeira, L, Trouboul, F, Valmar, C, Vegas, H, Venat-Bouvet, L, Zannetti, A, Bidard, FC, Delaloge, S, Bièche, I, Clatot, Florian, Canon, JL, André, F, Arnould, L, Berger, F, Marques, S

Get full text

Abstract P5-21-14: Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: Real-life results from the Curie ESME database by Kaczmarek, E, Saint-Martin, C, Pierga, J-Y, Brain, E, Rouzier, R, Dubot, C, Savignoni, A, Mouret-Fourme, E, Simon, G, Carton, M, Lerebours, F

Get full text

Abstract P4-01-20: Circulating tumor DNA as a predictive biomarker of response to palbociclib-fulvestrant in patients with estrogen receptor-positive, HER2-negative metastatic brea... by Darrigues, L, Pierga, J-Y, Bernard, A, Bièche, I, Silveira, A, Michel, M, Sablin, M-P, Cottu, P, Dubot, C, Geiss, R, Ricci, F, Proudhon, C, Bidard, F-C

Get full text

19P HER2-low prognosis in early breast cancer: A CANTO based study (LILAC) by Durand, L., Cherifi, F., Emile, G., Blanc-Fournier, C., Morel, A., Johnson, A.C., Rottier, P., Hrab, I., Desbois, P., Boscher, C., Levy, C., Dubot, C., Gunzer, K., Bimont, B., Segura-Djezzar, C., Allouache, D., Lequesne, J., Christy, F., Da Silva, A.

Get full text

Abstract P2-01-02: Heterogeneity and variability of human epidermal growth factor receptor 2 (HER2) expression on circulating tumor cells (CTC) in HER2 negative metastatic breast c... by Pierga, J-Y, Proudon, C, Tredan, O, Decraene, C, Dubot, C, Lorgis, V, Jacot, W, Goncalves, A, Debled, M, Levy, C, Ferrero, J-M, Jouannaud, C, Luporsi, E, Mouret-Reynier, M-A, Dalenc, F, Lemonnier, J, Berger, F, Bidard, F-C

Get full text

Rickettsia felis Infections and comorbid conditions, Laos, 2003-2011 by Dittrich, Sabine, Phommasone, Koukeo, Anantatat, Tippawan, Panyanivong, Phonepasith, Slesak, Günther, Blacksell, Stuart D, Dubot-Pérès, Audrey, Castonguay-Vanier, Josée, Stenos, John, Newton, Paul N, Paris, Daniel H

Get full text

Abstract OT1-02-03: Phase I multicenter clinical trial evaluating the combination of trastuzumab emtansine (T-DM1) and non-pegylated liposomal doxorubicin (NPLD) in HER2-positive m... by López-Miranda, E, Brain, E, Saura, C, Gligorov, J, Dubot, C, Dieras, V, Suter, TM, Aguirre, E, Perez-García, JM, Llombart, A, Cortés, J

Get full text